Ameritas Investment Partners’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $343K | Buy |
13,351
+1,697
| +15% | +$34.9K | 0.01% | 1066 |
|
|
2026
Q1 | $224K | Buy |
11,654
+589
| +5% | +$11.7K | 0.01% | 1203 |
|
|
2025
Q4 | $183K | Hold |
11,065
| – | – | 0.01% | 1311 |
|
|
2025
Q3 | $161K | Sell |
11,065
-2,457
| -18% | -$35.3K | ﹤0.01% | 1372 |
|
|
2025
Q2 | $189K | Buy |
13,522
+930
| +7% | +$13.1K | 0.01% | 1323 |
|
|
2025
Q1 | $171K | Hold |
12,592
| – | – | 0.01% | 1360 |
|
|
2024
Q4 | $257K | Hold |
12,592
| – | – | 0.01% | 1173 |
|
|
2024
Q3 | $367K | Buy |
12,592
+362
| +3% | +$8.97K | 0.01% | 966 |
|
|
2024
Q2 | $284K | Hold |
12,230
| – | – | 0.01% | 1044 |
|
|
2024
Q1 | $251K | Hold |
12,230
| – | – | 0.01% | 1138 |
|
|
2023
Q4 | $262K | Buy |
12,230
+492
| +4% | +$9.74K | 0.01% | 1106 |
|
|
2023
Q3 | $242K | Buy |
11,738
+1,982
| +20% | +$50.3K | 0.01% | 1069 |
|
|
2023
Q2 | $288K | Buy |
9,756
+1,047
| +12% | +$29.4K | 0.01% | 945 |
|
|
2023
Q1 | $201K | Hold |
8,709
| – | – | 0.01% | 1094 |
|
|
2022
Q4 | $259K | Buy |
8,709
+1,240
| +17% | +$36.9K | 0.01% | 994 |
|
|
2022
Q3 | $229K | Hold |
7,469
| – | – | 0.01% | 996 |
|
|
2022
Q2 | $219K | Buy |
7,469
+335
| +5% | +$8.78K | 0.01% | 1019 |
|
|
2022
Q1 | $230K | Hold |
7,134
| – | – | 0.01% | 1096 |
|
|
2021
Q4 | $318K | Hold |
7,134
| – | – | 0.01% | 948 |
|
|
2021
Q3 | $360K | Hold |
7,134
| – | – | 0.01% | 883 |
|
|
2021
Q2 | $560K | Buy |
7,134
+2,019
| +39% | +$125K | 0.02% | 762 |
|
|
2021
Q1 | $292K | Sell |
5,115
-153
| -3% | -$10.2K | 0.01% | 965 |
|
|
2020
Q4 | $441K | Sell |
5,268
-287
| -5% | -$17.4K | 0.02% | 800 |
|
|
2020
Q3 | $199K | Hold |
5,555
| – | – | 0.01% | 1033 |
|
|
2020
Q2 | $134K | Buy |
5,555
+1,362
| +32% | +$32K | 0.01% | 1239 |
|
|
2020
Q1 | $73K | Hold |
4,193
| – | – | ﹤0.01% | 1441 |
|
|
2019
Q4 | $73K | Buy |
4,193
+488
| +13% | +$8.12K | ﹤0.01% | 1688 |
|
|
2019
Q3 | $57K | Hold |
3,705
| – | – | ﹤0.01% | 1811 |
|
|
2019
Q2 | $77K | Hold |
3,705
| – | – | ﹤0.01% | 1662 |
|
|
2019
Q1 | $86K | Hold |
3,705
| – | – | ﹤0.01% | 1564 |
|
|
2018
Q4 | $77K | Hold |
3,705
| – | – | ﹤0.01% | 1559 |
|
|
2018
Q3 | $81K | Buy |
3,705
+2,343
| +172% | +$38.8K | ﹤0.01% | 1695 |
|
|
2018
Q2 | $21K | Hold |
1,362
| – | – | ﹤0.01% | 2482 |
|
|
2018
Q1 | $27K | Buy |
+1,362
| New | +$28K | ﹤0.01% | 2262 |
|
Other funds holding DNLI
Ameritas Investment Partners's DNLI Position: Q2 2026 in Review
Ameritas Investment Partners increased its Denali Therapeutics (DNLI) stake by 15% in Q2 2026, buying an estimated $34.9K and bringing the position to 13,351 shares worth $343K. The position accounts for 0.01% of the portfolio, ranked #1066.
Ameritas Investment Partners first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $560K in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- Ameritas Investment Partners held 13,351 shares of Denali Therapeutics worth $343K as of Q2 2026.
- Ameritas Investment Partners bought 1,697 Denali Therapeutics shares in Q2 2026, an estimated $34.9K.
- Denali Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1066 holding.
- Ameritas Investment Partners first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Ameritas Investment Partners's Denali Therapeutics position peaked at $560K in Q2 2021.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.